Colivelin

Catalog No.S9664 Synonyms: CLN

For research use only.

Colivelin (CLN) is a brain-penetrant neuroprotective peptide with potent long-term capacity against deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease. Colivelin is an activator of STAT3.

Colivelin Chemical Structure

CAS No. 867021-83-8

Selleck's Colivelin has been cited by 3 Publications

Purity & Quality Control

Choose Selective STAT Inhibitors

Other STAT Products

Biological Activity

Description Colivelin (CLN) is a brain-penetrant neuroprotective peptide with potent long-term capacity against deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease. Colivelin is an activator of STAT3.
Targets
[1] STAT3 [1]
In vitro

Colivelin, a brain penetrant neuroprotective peptide, significantly increases the p-STAT3 protein levels in BV-2 cells.<sup><a class="sref"href="#s_ref">[2]</a></sup>

In vivo

Colivelin protects against ischemic brain injury and improves neurological outcomes, by elevating anti-apoptotic genes up-regulation and activates JAK/STAT3 signaling afetr ischemic stroke.<sup><a class="sref"href="#s_ref">[1]</a></sup>

Protocol (from reference)

Cell Research:

<sup><a class="sref"href="#s_ref">[2]</a></sup>

  • Cell lines: BV-2 cells
  • Concentrations: 50 µg/ml
  • Incubation Time: 4 h
  • Method:

    BV-2 cells are maintained at 37℃ with 5% CO<sub>2</sub>. To build OGD models, BV-2 cells are washed with PBS for 3 times, and cultured in glucose-free DMEN and placed in a hypoxia incubation chamber filled with the gas mixture for 4 h at 37℃. The culture medium is then replaced by the normal medium containing 4.5 g/L glucose and cells are cultured under normoxic conditions for reoxygenation for 24 h. BV-2 cells are treated with 50 µg/ml rmMFG-E8 or/and Colivelin TFA, respectively. The expression changes of proteins (p-STAT3 and SOCS3) are analyzed by Western blot assay.

Animal Research:

<sup><a class="sref"href="#s_ref">[1]</a></sup>

  • Animal Models: Male C57BL/6 mice of middle cerebral artery occlusion (MCAO) models
  • Dosages: 1 mg/kg
  • Administration: i.p.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 2645.10
Formula

C119H206N32O35

CAS No. 867021-83-8
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCC(C)C(C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(C(C)O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(C)NC(=O)CNC(=O)C(C)NC(=O)C2CCCN2C(=O)C(C)NC(=O)C3CCCN3C(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CO)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05143996 Recruiting Drug: CLN-049 Relapsed/Refractory AML Cullinan Oncology LLC November 18 2021 Phase 1
NCT04974307 Recruiting Device: OrCam MyEye 2 CLN3-related Disorders|Low Vision Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC) September 30 2021 Not Applicable
NCT04637282 Not yet recruiting Drug: PLX-200|Drug: Placebo Juvenile Neuronal Ceroid Lipofuscinosis Polaryx Therapeutics Inc. September 1 2021 Phase 3
NCT04480476 Withdrawn -- Late-infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Regenxbio Inc. March 31 2021 --
NCT04462692 Withdrawn -- Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Regenxbio Inc. March 31 2021 --

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Colivelin | Colivelin supplier | purchase Colivelin | Colivelin cost | Colivelin manufacturer | order Colivelin | Colivelin distributor